TY - JOUR
T1 - Characteristics, management, and outcomes of patients with left-sided infective endocarditis complicated by heart failure
T2 - a substudy of the ESC-EORP EURO-ENDO (European infective endocarditis) registry
AU - Bohbot, Yohann
AU - Habib, Gilbert
AU - Laroche, C. cile
AU - Stöhr, Elisabeth
AU - Chirouze, Catherine
AU - Hernandez-Meneses, Marta
AU - Melissopoulou, Maria
AU - Mutlu, B. lent
AU - Scheggi, Valentina
AU - Branco, Luísa
AU - Olmos, Carmen
AU - Reyes, Graciela
AU - Pazdernik, Michal
AU - Iung, Bernard
AU - Sow, Rouguiatou
AU - Mirocevic, Maja
AU - Lancellotti, Patrizio
AU - Tribouilloy, Christophe
AU - EORP EURO-ENDO Registry Investigators Group
AU - Gale, C. P.
AU - Beleslin, B.
AU - Budaj, A.
AU - Chioncel, O.
AU - Dagres, N.
AU - Danchin, N.
AU - Emberson, J.
AU - Erlinge, D.
AU - Glikson, M.
AU - Gray, A.
AU - Kayikcioglu, M.
AU - Maggioni, A. P.
AU - Nagy, V. K.
AU - Nedoshivin, A.
AU - Petronio, A. S.
AU - Roos-Hesselink, J.
AU - Wallentin, L.
AU - Zeymer, U.
AU - Habib, G.
AU - Lancellotti, P.
AU - Cosyns, B.
AU - Donal, E.
AU - Erba, P.
AU - Iung, B.
AU - Maggioni, A. P.
AU - Popescu, B. A.
AU - Prendergast, B.
AU - Kamp, O.
AU - Fischer, C.
AU - Ali, M.
AU - Meijers, T.
AU - Rodrigues, G.
AU - Heger, M.
AU - Takahashi, K.
AU - Chamuleau, S.
AU - van der Bilt, I.
AU - Stojanovic, I.
AU - Bel, A.
N1 - Funding Information: This work was supported by Abbott Vascular Int. (2011–2014), Amgen Cardiovascular (2009–2018), AstraZeneca (2014–2020), Bayer AG (2009–2018), Boehringer Ingelheim (2009–2019), Boston Scientific (2009–2012), The Bristol Myers Squibb and Pfizer Alliance (2011–2019), Daiichi Sankyo Europe GmbH (2011–2020), The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company (2014–2017), Edwards (2016–2019), Gedeon Richter Plc. (2014–2016), Menarini Int. Op. (2009–2012), MSD-Merck & Co. (2011–2014), Novartis Pharma AG (2014–2020), ResMed (2014–2016), Sanofi (2009–2011), Servier (2009–2018), Vifor (2019–2022). Conflict of interest: none declared. EURObservational Research Programme EORP Oversight Committee, Registry Executive and Steering Committees of the Data collection was conducted by the EORP department of the ESC: Emanuela Fiorucci, as Project Officer; Viviane Missiamenou, Florian Larras, and Rachid Mir Hassaine, as Data Managers. Statistical analyses were performed by Cécile Laroche. Overall activities were coordinated and supervised by Doctor Aldo P. Maggioni (EORP Scientific Coordinator). Special thanks to the EACVI (European Association of CardioVascular Imaging) and to the ESC Working Group on Valvular Heart Disease for their support. This work was supported by Abbott Vascular Int. (2011–2014), Amgen Cardiovascular (2009–2018), AstraZeneca (2014–2020), Bayer AG (2009–2018), Boehringer Ingelheim (2009–2019), Boston Scientific (2009–2012), The Bristol Myers Squibb and Pfizer Alliance (2011–2019), Daiichi Sankyo Europe GmbH (2011–2020), The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company (2014–2017), Edwards (2016–2019), Gedeon Richter Plc. (2014–2016), Menarini Int. Op. (2009–2012), MSD-Merck & Co. (2011–2014), Novartis Pharma AG (2014–2020), ResMed (2014–2016), Sanofi (2009–2011), Servier (2009–2018), Vifor (2019–2022). Conflict of interest: none declared. Publisher Copyright: © 2022 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
PY - 2022/7/1
Y1 - 2022/7/1
N2 - Aims: To evaluate the current management and survival of patients with left-sided infective endocarditis (IE) complicated by congestive heart failure (CHF) in the ESC-EORP European Endocarditis (EURO-ENDO) registry. Methods and results: Among the 3116 patients enrolled in this prospective registry, 2449 (mean age: 60 years, 69% male) with left-sided (native or prosthetic) IE were included in this study. Patients with CHF (n = 698, 28.5%) were older, with more comorbidity and more severe valvular damage (mitro-aortic involvement, vegetations >10 mm and severe regurgitation/new prosthesis dehiscence) than those without CHF (all p ≤ 0.019). Patients with CHF experienced higher 30-day and 1-year mortality than those without (20.5% vs. 9.0% and 36.1% vs. 19.3%, respectively) and CHF remained strongly associated with 30-day (odds ratio[OR] 2.37, 95% confidence interval [CI] [1.73–3.24; p < 0.001) and 1-year mortality (hazard ratio [HR] 1.69, 95% CI 1.39–2.05; p < 0.001) after adjustment for established outcome predictors, including early surgery, or after propensity matching for age, sex, and comorbidity (n = 618 [88.5%] for each group, both p < 0.001). Early surgery, performed on 49% of these patients with IE complicated by CHF, remained associated with a substantial reduction in 30-day mortality following multivariable analysis, after adjustment for age, sex, Charlson comorbidity index, cerebrovascular accident, Staphylococcus aureus IE, streptococcal IE, uncontrolled infection, vegetation size >10 mm, severe valvular regurgitation and/or new prosthetic dehiscence, perivalvular complication, and prosthetic IE (OR 0.22, 95% CI 0.12–0.38; p < 0.001) and in 1-year mortality (HR 0.29, 95% CI 0.20–0.41; p < 0.001). Conclusion: Congestive heart failure is common in left-sided IE and is associated with older age, greater comorbidity, more advanced lesions, and markedly higher 30-day and 1-year mortality. Early surgery is strongly associated with lower mortality but is performed on only approximately half of patients with CHF, mainly because of a surgical risk considered prohibitive.
AB - Aims: To evaluate the current management and survival of patients with left-sided infective endocarditis (IE) complicated by congestive heart failure (CHF) in the ESC-EORP European Endocarditis (EURO-ENDO) registry. Methods and results: Among the 3116 patients enrolled in this prospective registry, 2449 (mean age: 60 years, 69% male) with left-sided (native or prosthetic) IE were included in this study. Patients with CHF (n = 698, 28.5%) were older, with more comorbidity and more severe valvular damage (mitro-aortic involvement, vegetations >10 mm and severe regurgitation/new prosthesis dehiscence) than those without CHF (all p ≤ 0.019). Patients with CHF experienced higher 30-day and 1-year mortality than those without (20.5% vs. 9.0% and 36.1% vs. 19.3%, respectively) and CHF remained strongly associated with 30-day (odds ratio[OR] 2.37, 95% confidence interval [CI] [1.73–3.24; p < 0.001) and 1-year mortality (hazard ratio [HR] 1.69, 95% CI 1.39–2.05; p < 0.001) after adjustment for established outcome predictors, including early surgery, or after propensity matching for age, sex, and comorbidity (n = 618 [88.5%] for each group, both p < 0.001). Early surgery, performed on 49% of these patients with IE complicated by CHF, remained associated with a substantial reduction in 30-day mortality following multivariable analysis, after adjustment for age, sex, Charlson comorbidity index, cerebrovascular accident, Staphylococcus aureus IE, streptococcal IE, uncontrolled infection, vegetation size >10 mm, severe valvular regurgitation and/or new prosthetic dehiscence, perivalvular complication, and prosthetic IE (OR 0.22, 95% CI 0.12–0.38; p < 0.001) and in 1-year mortality (HR 0.29, 95% CI 0.20–0.41; p < 0.001). Conclusion: Congestive heart failure is common in left-sided IE and is associated with older age, greater comorbidity, more advanced lesions, and markedly higher 30-day and 1-year mortality. Early surgery is strongly associated with lower mortality but is performed on only approximately half of patients with CHF, mainly because of a surgical risk considered prohibitive.
KW - Congestive heart failure
KW - EURO-ENDO
KW - Early surgery
KW - Infective endocarditis
KW - Outcome
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=85131751367&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/ejhf.2525
DO - https://doi.org/10.1002/ejhf.2525
M3 - Article
C2 - 35508915
SN - 1388-9842
VL - 24
SP - 1253
EP - 1265
JO - European journal of heart failure
JF - European journal of heart failure
IS - 7
ER -